CDK4 and breast cancer: The use of a combination of CDK4 and CDK6 inhibitors (CDK4/6) with endocrine therapy for the treatment of HR+ and HER2− breast cancer improves overall survival [22], and increases the proportion of patients with a long-term response [23].